BROADWOOD PARTNERS, L.P. 4

What Happened
Broadwood Partners, L.P. (reported as a 10% owner) acquired a total of 182,861 shares of Insight Molecular Diagnostics, Inc. (IMDX) in a series of open-market/private purchases between April 16 and April 20, 2026. Transactions reported: 102,057 shares at $3.45 on 4/16 ($351,658); 40,114 shares at $3.57 on 4/17 ($143,251); and 40,690 shares at $3.88 on 4/20 (~$157,967). Aggregate value of these purchases is about $652,900. These were purchases (code P), not sales.

Key Details

• Transaction dates & prices: 4/16 @ $3.45 (102,057); 4/17 @ $3.57 (40,114); 4/20 @ $3.88 (40,690).
• Total shares acquired: 182,861; total consideration: ≈ $652,876.
• Shares owned after transaction: not stated in the filing.
• Footnotes of note:
  • F1: Securities are directly owned by Broadwood Partners and may be deemed beneficially owned by Broadwood Capital, Inc. and Neal C. Bradsher; each disclaims beneficial ownership except to extent of pecuniary interest.
  • F3–F5: Reported weighted-average prices cover ranges ($3.20–$3.99 across ranges); the filer will provide breakdowns of purchases at each price upon request.
  • F6 noted (some warrants are currently exercisable) but the filing does not tie those warrants to these specific purchases.
• Filing timeliness: filing dated Apr 20, 2026 for transactions Apr 16–20; filing does not indicate a late report.

Context

• This report reflects institutional/investor purchases by a 10% owner, not an employee/board member trade. For retail investors, purchases by large holders can signal an increase in stake but are not a direct statement of company prospects.
• Transactions are simple purchases (code P); there are no option exercises, awards, or sales reported in this filing.